Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020).
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Abate D, Abbasi N et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 5(12), 1749–1768 (2019).
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Chen D, Ye Y, Guo S, Yao K. Progress in the research and targeted therapy of ErbB/HER receptors in urothelial bladder cancer. Front. Mol. Biosci. 8, 800945 (2021).
   PubMed Web of Science ®Google Scholar
• Hepp Z, Shah SN, Smoyer K, Vadagam P. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis. J. Manag. Care. Spec. Pharm. 27(2), 240–255 (2021).
   PubMed Web of Science ®Google Scholar
• Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J. Clin. 70(5), 404–423 (2020).
   PubMed Web of Science ®Google Scholar
• Grisay G, Pierrard J, Confente C, Seront E. Future strategies involving immune checkpoint inhibitors in advanced urothelial carcinoma. Curr. Treat. Options Oncol. 22(1), 7 (2020).
   PubMed Web of Science ®Google Scholar
• Amin MB, Mckenney JK, Paner GP et al. ICUD-EAU international consultation on bladder cancer 2012: pathology. Eur. Urol. 63(1), 16–35 (2013).
   PubMed Web of Science ®Google Scholar
• Park I, Lee JL. Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options. Korean J. Intern. Med. 35(4), 834–853 (2020).
   PubMed Web of Science ®Google Scholar
• Kearney M, Knott C, Lamy FX, Harnett J, Amin A, Verpillat P. Treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial cancer in England: results of a longitudinal observational cohort study. Value Health. 23(Suppl. 2), S483 (2020).
   Google Scholar
• Bilen Ma XA, Wong A, Peng J, Robinson S, Bhanegaonkar A. Real-world treatment patterns and clinical outcomes in patients with metastatic urothelial carcinoma (mUC) receiving first-line (1L) treatment: results from IMPACT UC. Ann. Oncol. 32(Suppl. 5), S713 (2021).
   Google Scholar
• Geynisman DM, Broughton E, Hao Y, Zhang Y, Le T, Huo S. Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States. Urol. Oncol. 40(5), 195e191–195e111 (2022).
   Web of Science ®Google Scholar
• Morgans AK, Galsky MD, Hepp Z et al. 704P Treatment patterns among patients with advanced urothelial carcinoma (aUC) in the USA. Ann. Oncol. 32, S714–S715 (2021).
   Google Scholar
• Witjes JA, Bruins HM, Carrión A et al. EAU guideline on muscle-invasive and metastatic bladder cancer (2023). https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer
   Google Scholar
• Cathomas R, Lorch A, Bruins HM et al. The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur. Urol. 81(1), 95–103 (2022).
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer, Version 3.2023 (2023). https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
   Google Scholar
• Powles T, Bellmunt J, Comperat E et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33(3), 244–258 (2022).
   PubMed Web of Science ®Google Scholar
• De Santis M, Bellmunt J, Mead G et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J. Clin. Oncol. 30(2), 191–199 (2012).
   PubMed Web of Science ®Google Scholar
• Galsky MD, Chen GJ, Oh WK et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann. Oncol. 23(2), 406–410 (2012).
   PubMed Web of Science ®Google Scholar
• Galsky MD, Hahn NM, Rosenberg J et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J. Clin. Oncol. 29(17), 2432–2438 (2011).
   PubMed Web of Science ®Google Scholar
• Powles T, Park SH, Voog E et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 383(13), 1218–1230 (2020).
   PubMed Web of Science ®Google Scholar
• Swami U, Grivas P, Pal SK, Agarwal N. Utilization of systemic therapy for treatment of advanced urothelial carcinoma: lessons from real world experience. Cancer Treat. Res. Commun. 27, 100325 (2021).
   PubMedGoogle Scholar
• Vafaei-Nodeh S, Beigi A, Huang L, Mimmack G, Sun SZ, Ko JJ. Survival outcomes associated with different palliative systemic therapies (PSTs) in patients with metastatic bladder cancer (mBC). J. Clin. Oncol. 38(6), abstract 450 (2020).
   Web of Science ®Google Scholar
• Richters A, Mehra N, Meijer RP et al. Utilization of systemic treatment for metastatic bladder cancer in everyday practice: results of a nation-wide population-based cohort study. Cancer Treat Res. Commun. 25, 100266 (2020).
   PubMedGoogle Scholar
• Reesink DJ, Van De Garde EMW, Peters BJM et al. Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands. Sci. Rep. 10(1), 15822 (2020).
   PubMed Web of Science ®Google Scholar
• Petkau V, Alekseeva G, Zukov R et al. The association of access to systemic therapy and overall survival in metastatic bladder cancer in Russia: an analysis of URRU register. J. Clin. Oncol. 39(28), abstract 88 (2021).
   Web of Science ®Google Scholar
• Fisher MD, Shenolikar R, Miller PJ, Fenton M, Walker MS. Treatment patterns and outcomes in stage iv bladder cancer in a community oncology setting: 2008–2015. Clin. Genitourin. Cancer. 16(6), e1171–e1179 (2018).
   PubMed Web of Science ®Google Scholar
• Doshi G, Bhanegaonkar A, Bharmal M et al. PCN339 - SPEAR-BLADDER (study informing treatment pathway decision in bladder cancer): timing of treatment following first-line therapy in patients with locally advanced and metastatic urothelial cancer in the community oncology setting in the United States. Value Health. 21, S72 (2018).
   Web of Science ®Google Scholar
• Russo L, Esposito D, Lamy F-X et al. Characteristics, treatment patterns and safety events from 4 cohorts of advanced or metastatic cancer patients based on health care claims data. J. Clin. Oncol. 36(Suppl. 15), e13603 (2018).
   Google Scholar
• Parikh RB, Galsky MD, Gyawali B et al. Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma at the end of life: insights from real-world practice. Oncologist. 24(6), e397–e399 (2019).
   PubMed Web of Science ®Google Scholar
• Flannery K, Boyd M, Black-Shinn J, Robert N, Kamat AM. Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study. Future Oncol. 15(12), 1323–1334 (2019).
   PubMed Web of Science ®Google Scholar
• Pollock G, Hsu CH, Batai K, Lee BR, Chipollini J. Postoperative and survival outcomes after cytoreductive surgery in the treatment of metastatic upper tract urothelial carcinoma. Urology 153, 244–249 (2021).
   PubMed Web of Science ®Google Scholar
• Mao W, Ma B, Huang X et al. Which treatment is best for patients with AJCC stage IV bladder cancer? Int. Urol. Nephrol. 51(7), 1145–1156 (2019).
   PubMed Web of Science ®Google Scholar
• Davies FJ, Knott C, Kerr C, Adedokun L, Lockhat DM. Utilising Public Health England datasets to establish a standing cohort of patients with metastatic bladder cancer: initial results and algorithm defining disease progression. Value Health. 23(Suppl. 2), S480–S481 (2020).
   Google Scholar
• Sevillano E, Rodriguez-Moreno JF, Barquin A et al. Clinical outcome in terms of survival and treatment response of patients with metastatic urothelial carcinoma harboring FGFR alterations compared to wild-type tumors. J. Clin. Oncol. 38(Suppl. 15), e17042 (2020).
   Web of Science ®Google Scholar
• Richters A, Boormans JL, van der Heijden MS et al. Overall survival of patients receiving cisplatin or carboplatin for primary metastatic urothelial carcinoma of the bladder: a contemporary Dutch nationwide cohort study. Eur. Urol. Focus 8(14), 995–1002 (2022).
   PubMedGoogle Scholar
• Jensen JB, Hauberg DS, Duus Hjortsoe M, Madsen ME, Olsen J, Agerbaek M. Treatment pattern and overall survival among patients with locally advanced or metastatic urothelial carcinoma: results from a complete nationwide unselected real-world registry study in Denmark from 2010 to 2017. Ann. Oncol. 32(5), S716 (2021).
   Google Scholar
• Fukushima H, Nakanishi Y, Kataoka M, Tobisu K-I, Koga F. Prognostic significance of serum γ-glutamyltransferase in advanced urothelial carcinoma patients. J. Urol. 197(4), e433–434 (2017).
   Web of Science ®Google Scholar
• Miyake M, Shimizu T, Nishimura N et al. Response to pembrolizumab after dose-reduced cisplatin plus gemcitabine chemotherapy is inferior to that after carboplatin plus gemcitabine chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma. Clin. Genitourin. Cancer. 20(2), 196e191–196e199 (2022).
   Web of Science ®Google Scholar
• Diamantopoulos LN, Khaki AR, Sonpavde GP et al. Central nervous system metastasis in patients with urothelial carcinoma: institutional experience and a comprehensive review of the literature. Clin. Genitourin. Cancer. 18(3), e266–276 (2020).
   PubMed Web of Science ®Google Scholar
• Abu-Hijlih RA, Salah S, Al-Ibraheem A et al. Bladder cancer in young adults: disease and treatment characteristics of patients treated at tertiary cancer center. J. Clin. Oncol. 39(Suppl. 15), e16521 (2021).
   Google Scholar
• Park K, Nam JK, Koo BJ et al. Clinical characteristics, treatment delivery, and cisplatin eligibility in Korean patients initially diagnosed with urothelial carcinoma. Ewha Med. J. 44(3), 63–69 (2021).
   Google Scholar
• Kohei N, Sugiyama K, Chihara I et al. Impact of relative dose intensity in gemcitabine-cisplatin chemotherapy for metastatic urothelial carcinoma. SAGE Open Med. 6, 2050312118783011 (2018).
   Google Scholar
• Ikeda M, Matsumoto K, Hirayama T et al. Oncologic outcomes of salvage chemotherapy in patients with recurrent or metastatic lesions after radical nephroureterectomy: a multi-institutional retrospective study. Chemotherapy 65(5–6), 134–140 (2020).
   PubMed Web of Science ®Google Scholar
• Grass GD, Awasthi S, Jain R et al. A population-based assessment of local therapy for de novo oligometastatic urothelial carcinoma of the bladder. Int. J. Radiat. Oncol. Biol. Physics. 111(3), E259 (2021).
   Web of Science ®Google Scholar
• Sørup S, Darvalics B, Kearney M et al. Treatment patterns, clinical outcomes, and healthcare resource use among patients with stage IV urothelial cancer: findings from a nationwide cohort study in Denmark. Value Health. 24(Suppl. 1), S65 (2021).
   Google Scholar
• Okuyama A, Higashi T. Patterns of cancer treatment in different age groups in Japan: an analysis of hospital-based cancer registry data, 2012–2015. Jpn J. Clin. Oncol. 48(5), 417–425 (2018).
   PubMed Web of Science ®Google Scholar
• Aguilar KM, Grivas P, Seal B et al. Adoption of immune checkpoint inhibitors (ICI) for unresectable locally advanced or metastatic urothelial carcinoma (u/mUC): a retrospective assessment of community oncology practices. J. Clin. Oncol. 39 (Suppl. 28), 293 (2021).
   Web of Science ®Google Scholar
• Katayama S, Kobayashi Y, Takamoto A et al. Impact of paclitaxel, cisplatin, and gemcitabine as first-line chemotherapy in cisplatin-fit and -unfit patients with advanced/metastatic urothelial carcinoma. Urol. Oncol. Semin. Original Invest. 39(10), 731.e725–731.e732 (2021).
   Web of Science ®Google Scholar
• Klein A, Parikh R, Kurosky S, Esterberg E, Kaye JA. PCN311 Clinical characteristics, treatment patterns, and healthcare resource utilization in patients with advanced urothelial carcinoma after progression on platinum-based therapy: a medical record review study in the United States and Canada. Value Health. 22, S115 (2019).
   Web of Science ®Google Scholar
• Gomez de Liano Lista A, van Dijk N, de Velasco Oria de Rueda G et al. Clinical outcome after progressing to frontline and second-line anti-PD-1/PD-L1 in advanced urothelial cancer. Eur. Urol. 77(2), 269–276 (2020).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Mcdermott DF et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J. Immunother. Cancer. 8(2), e000891 (2020).
   PubMed Web of Science ®Google Scholar
• Gupta S, Su C, Bhanegaonkar A et al. Disease management and frontline treatment of locally advanced or metastatic urothelial (la/mUC) carcinoma: The U.S. physician PARADIGM study. J. Clin. Oncol. 39 (Suppl. 28), 293 (2022).
   Google Scholar
• Knott C, Kearney M, Mahmoudpour H, Verpillat P. 1750P Factors associated with receipt of systemic treatment (tx) for metastatic urothelial carcinoma (mUC) in England. Ann. Oncol. 33(Suppl. 7), S1338 (2022).
   Web of Science ®Google Scholar
• Gironés Sarrió R, Antonio Rebollo M, Molina Garrido MJ et al. General recommendations paper on the management of older patients with cancer: the SEOM geriatric oncology task force's position statement. Clin. Transl. Oncol. 20(10), 1246–1251 (2018).
   PubMed Web of Science ®Google Scholar
• Jodon G, Fischer SM, Kessler ER. Treatment of urothelial cancer in elderly patients: focus on immune checkpoint inhibitors. Drugs Aging 35(5), 409–421 (2018).
   PubMed Web of Science ®Google Scholar
• Mohile SG, Velarde C, Hurria A et al. Geriatric assessment-guided care processes for older adults: a Delphi consensus of geriatric oncology experts. J. Natl Compr. Cancer Network. 13(9), 1120–1130 (2015).
   PubMed Web of Science ®Google Scholar
• Aly A, Johnson C, Doleh Y, Shenolikar R, Botteman MF, Hussain A. Medical oncology referral and systemic therapy of patients with advanced stage urothelial carcinoma. J. Comp. Effectiveness Res. 9(13), 945–957 (2020).
   PubMed Web of Science ®Google Scholar
• Hupe MC, Merseburger AS, De Wit M, Rexer H, Gschwend JE, Krege S. Practice pattern of systemic therapy for urothelial cancer in Germany - a survey of the German cancer society. Aktuelle Urol. 49(4), 346–354 (2018).
   PubMed Web of Science ®Google Scholar
• Galsky MD, Ma E, Shah-Manek B et al. Cisplatin ineligibility for patients with metastatic urothelial carcinoma: a survey of clinical practice perspectives among US oncologists. Bladder Cancer. 5, 281–288 (2019).
   Web of Science ®Google Scholar
• Jindal K, Mendoza L, Moehler T, Anger C. Adoption of immune checkpoint inhibitors (ICIs) in bladder cancer: findings from a real-world study in EU5. Ann. Oncol. 31, S595 (2020).
   Google Scholar
• Gourd E. EMA restricts use of anti-PD-1 drugs for bladder cancer. Lancet Oncol. 19(7), e341 (2018).
   PubMed Web of Science ®Google Scholar
• Crist M, Iyer G, Hsu M, Huang WC, Balar AV. Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience. Ther. Adv. Urol. 11, 1756287219839285 (2019).
   Web of Science ®Google Scholar
• Powles T, Csőszi T, Özgüroğlu M et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 22(7), 931–945 (2021).
   PubMed Web of Science ®Google Scholar
• Stenehjem DD, Tran D, Nkrumah MA, Gupta S. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. Onco. Targets Ther. 11, 5973–5989 (2018).
   PubMed Web of Science ®Google Scholar
• ESMO Congress and ISPOR Europe (2022).
   Google Scholar